UB Paderborn / Katalog / Suche / in CDI

Covariate adjusted nonparametric methods under propensity analysis

Frontiers in applied mathematics and statistics, 2024-03, Vol.10

2024

Link zum Volltext

Verfügbarkeit prüfen

A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study

Clinical cancer research, 2021-03, Vol.27 (6), p.1631-1640

2021

Link zum Volltext

Verfügbarkeit prüfen

Optimal PD-L1-high cutoff for association with overall survival in patients with urothelial cancer treated with durvalumab monotherapy

PloS one, 2020-04, Vol.15 (4), p.e0231936-e0231936

2020

Link zum Volltext

Verfügbarkeit prüfen

Quantitative Safety Monitoring in Clinical Trials: Application of Multiple Statistical Methodologies for Infrequent Events

Therapeutic innovation & regulatory science, 2020-09, Vol.54 (5), p.1175-1184

2020

Link zum Volltext

Verfügbarkeit prüfen

Correlation Between Early Endpoints and Overall Survival in Non-Small-Cell Lung Cancer: A Trial-Level Meta-Analysis

Frontiers in oncology, 2021-07, Vol.11, p.672916-672916

2021

Link zum Volltext

Verfügbarkeit prüfen

Addressing the Impact of the COVID-19 Pandemic on Survival Outcomes in Randomized Phase III Oncology Trials

Journal of Data Science, 2023-10, Vol.21 (4), p.781-798

2023

Link zum Volltext

Verfügbarkeit prüfen

Empirical Power and Type I Error of Covariate Adjusted Nonparametric Methods

Mathematics and Statistics, 2022-09, Vol.10 (5), p.1050-1074

2022

Link zum Volltext

Verfügbarkeit prüfen

663 Correlation between early endpoints and overall survival in non-small-cell lung cancer: a trial-level meta-analysis

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A700-A700

2020

Link zum Volltext

Verfügbarkeit prüfen

Relationship Between Progression‐Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD‐1/PD‐L1 Immune Checkpoint Blockade: A Meta‐Analysis

Clinical pharmacology and therapeutics, 2020-12, Vol.108 (6), p.1274-1288

2020

Link zum Volltext

Verfügbarkeit prüfen

Robust Design and Analysis of Clinical Trials With Nonproportional Hazards: A Straw Man Guidance From a Cross-Pharma Working Group

Statistics in biopharmaceutical research, 2023-04, Vol.15 (2), p.280-294

2023

Link zum Volltext

Verfügbarkeit prüfen

Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Clinical cancer research, 2023-06, Vol.29 (11), p.2066-2074

2023

Link zum Volltext

Verfügbarkeit prüfen

Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis

JAMA oncology, 2022-09, Vol.8 (9), p.1294

2022

Link zum Volltext

Verfügbarkeit prüfen

Alternative Analysis Methods for Time to Event Endpoints Under Nonproportional Hazards: A Comparative Analysis

Statistics in biopharmaceutical research, 2020-04, Vol.12 (2), p.187-198

2020

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients

Clinical lung cancer, 2019-11, Vol.20 (6), p.e601-e608

2019

Link zum Volltext

Verfügbarkeit prüfen

Temporal Change in Tumor Volume Following Stereotactic Radiosurgery to a Single Brain Metastasis

World neurosurgery, 2020-04, Vol.136, p.e328-e333

2020

Link zum Volltext

Verfügbarkeit prüfen

Optimization of PD-L1 algorithm for predicting overall survival (OS) in patients with urothelial cancer (UC) treated with durvalumab monotherapy

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.4530-4530

2018

Link zum Volltext

Verfügbarkeit prüfen

Applications of Covariate Adjusted Nonparametric Methods to CCTRN Clinical Trials

Communication in statistics. Case studies and data analysis, 2022, Vol.8 (4), p.728-737

2022

Link zum Volltext

Verfügbarkeit prüfen

A phase III, randomized, open label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine+cisplatin (G+C) for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (MIBC) (NIAGARA)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.TPS4592-TPS4592

2019

Link zum Volltext

Verfügbarkeit prüfen

Plasma-based tumor mutational burden (bTMB) as predictor for survival in phase III EAGLE study: Durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum failure

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.6511-6511

2020

Link zum Volltext

Verfügbarkeit prüfen

Covariates adjustment for nonparametric tests for two sample comparison

Ye, Jiabu

2016

Link zum Volltext
ProQuest

Comment on "Non-Proportional Hazards - an Evaluation of the MaxCombo Test in Cancer Clinical Trials" by the Cross-Pharma Non-Proportional Hazards Working Group

Statistics in biopharmaceutical research, 2023-04, Vol.15 (2), p.312-314

2023

Link zum Volltext

Verfügbarkeit prüfen

Association of PD-L1 Expression on Tumor and Immune Cells with Survival in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Assay Validation

Cancer research communications, 2022-01, Vol.2 (1), p.39-48

2022

Link zum Volltext

Verfügbarkeit prüfen

Estimations of treatment effects based on covariate adjusted nonparametric methods

Cogent mathematics & statistics, 2020-01, Vol.7 (1), p.1750878

2020

Link zum Volltext

Verfügbarkeit prüfen

Applications of covariate adjusted nonparametric methods to CCTRN clinical trials

Communications in Statistics: Case Studies, Data Analysis and Applications, 2022, Vol.8 (4), p.728-737

2022

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Covariate adjusted nonparametric methods under propensity analysis

A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study

Optimal PD-L1-high cutoff for association with overall survival in patients with urothelial cancer treated with durvalumab monotherapy

Quantitative Safety Monitoring in Clinical Trials: Application of Multiple Statistical Methodologies for Infrequent Events

Correlation Between Early Endpoints and Overall Survival in Non-Small-Cell Lung Cancer: A Trial-Level Meta-Analysis

Addressing the Impact of the COVID-19 Pandemic on Survival Outcomes in Randomized Phase III Oncology Trials

Empirical Power and Type I Error of Covariate Adjusted Nonparametric Methods

663 Correlation between early endpoints and overall survival in non-small-cell lung cancer: a trial-level meta-analysis

Relationship Between Progression‐Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD‐1/PD‐L1 Immune Checkpoint Blockade: A Meta‐Analysis

Robust Design and Analysis of Clinical Trials With Nonproportional Hazards: A Straw Man Guidance From a Cross-Pharma Working Group

Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis

Alternative Analysis Methods for Time to Event Endpoints Under Nonproportional Hazards: A Comparative Analysis

Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients

Temporal Change in Tumor Volume Following Stereotactic Radiosurgery to a Single Brain Metastasis

Optimization of PD-L1 algorithm for predicting overall survival (OS) in patients with urothelial cancer (UC) treated with durvalumab monotherapy

Applications of Covariate Adjusted Nonparametric Methods to CCTRN Clinical Trials

A phase III, randomized, open label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine+cisplatin (G+C) for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (MIBC) (NIAGARA)

Plasma-based tumor mutational burden (bTMB) as predictor for survival in phase III EAGLE study: Durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum failure

Covariates adjustment for nonparametric tests for two sample comparison

Comment on "Non-Proportional Hazards - an Evaluation of the MaxCombo Test in Cancer Clinical Trials" by the Cross-Pharma Non-Proportional Hazards Working Group

Association of PD-L1 Expression on Tumor and Immune Cells with Survival in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Assay Validation

Estimations of treatment effects based on covariate adjusted nonparametric methods

Applications of covariate adjusted nonparametric methods to CCTRN clinical trials

Suchergebnisse filtern